What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short version

• The FDA has stepped up enforcement and public warnings about compounded GLP‑1 drugs (copies of semaglutide, tirzepatide, etc.). The agency’s position: making and marketing unapproved “copies” of FDA‑approved GLP‑1 products raises safety and legal problems, and some compounders doing that have been warned or targeted.
• What remains clearly legal: dispensing FDA‑approved GLP‑1 medicines (brand products) through standard pharmacies, and compounding done legitimately under federal/state compounding rules (see 503A and 503B below) when it truly meets the narrow statutory requirements.
• If you need a GLP‑1, the safest route is an FDA‑approved product (examples: Ozempic/Wegovy — Novo Nordisk; Mounjaro/Zepbound — Eli Lilly) dispensed by a licensed pharmacy. If you’re considering a compounded product, only use a facility that can document it is operating within the law and meets sterility/testing standards.

What the FDA did and why

• FDA warnings and communications: The agency warned the public that some compounding pharmacies were producing and selling compounded GLP‑1 products that (a) are essentially copies of approved biologics/peptide drugs, (b) may be made from unverified bulk ingredients, and (c) may present sterility, dosing, labeling and safety risks. FDA has issued public advisories and, in some cases, taken regulatory/enforcement steps (warning letters, seizure actions, referrals to state boards or DOJ) against companies it found were operating outside the law.
• Legal basis: Federal drug law (and FDA policy) restricts compounding of unapproved copies of FDA‑approved drugs and generally prohibits compounding of certain biological products. Compounded products also escape the manufacturing controls and post‑market monitoring that approved drugs undergo, creating safety concerns.

Key legal distinctions (helps understand who can operate legally)

• 503A pharmacies (traditional state‑licensed compounding pharmacies): May lawfully compound patient‑specific prescriptions in response to a valid prescription for an identified individual. They are regulated primarily by state boards of pharmacy and must follow state and USP compounding standards. They are not supposed to engage in large‑scale production or routinely compound copies of approved drugs.
• 503B outsourcing facilities: Registered with FDA; they can produce larger batches for health‑care facility use and are subject to current Good Manufacturing Practice (cGMP) rules and FDA inspection. But outsourcing facilities are also not permitted to compound exact copies of approved drugs or certain biologics.
• Bottom line: Some compounding is legal — but it is tightly constrained. Compounding a copy of an FDA‑approved GLP‑1 product for broad distribution is what the FDA objects to.

Who is still operating legally

• FDA‑approved manufacturers and normal pharmacies: Brands like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) are legal and continue to be manufactured and dispensed through normal distribution channels and pharmacies (CVS, Walgreens, Walmart, independent retail pharmacies).
• Compounding pharmacies: Some 503A pharmacies and 503B outsourcing facilities continue to operate legally — but only if they follow the applicable rules: they must have a valid prescription for an identified patient (503A), or be a registered 503B and comply with cGMP and FDA requirements. They must not produce prohibited copies of biologics or otherwise violate FDA/state rules. Because of the FDA warnings, many compounding pharmacies have stopped making GLP‑1 products or adjusted practices to reduce legal risk.
• How to know if a compounding provider is legal: verify state pharmacy licensure for 503A; check the FDA’s list of registered 503B outsourcing facilities; check for any FDA warning letters or state board actions against the pharmacy; confirm they require a valid prescription; ask for certificates of analysis (COAs) for active ingredients and evidence of sterility testing and USP compliance.

Safety and practical advice

• Prefer FDA‑approved products when possible (Ozempic, Wegovy — Novo Nordisk; Mounjaro, Zepbound — Eli Lilly). These are made under controlled manufacturing and safety-monitoring systems.
• If cost or access is the issue, explore manufacturer assistance programs (Novo Nordisk and Eli Lilly both have patient support programs), authorized telehealth services and discounts through pharmacies or coupon services (GoodRx, SingleCare).
• If you’re considering a compounded GLP‑1: insist on a valid prescription, verify the pharmacy’s legal status (state license or FDA 503B registration), get COAs for ingredients, inquire about sterility testing and USP <797>/<800> compliance, and check that the pharmacy has not been the subject of an FDA warning letter or state action.

If you want, I can:

• Look up whether a particular compounding pharmacy or outsourcing facility is currently registered or has an FDA warning letter (tell me the name and state), or
• Give step‑by‑step questions to ask a compounding pharmacy to verify safety and legality.